Altered Insulin Signaling in Alzheimer's Disease Brain - Special Emphasis on PI3K-Akt Pathway.

Gabbouj S, Ryhänen S, Marttinen M, Wittrahm R, Takalo M, Kemppainen S, Martiskainen H, Tanila H, Haapasalo A, Hiltunen M, Natunen T. · 2019

Read Altered Insulin Signaling in Alzheimer's Disease Brain - Special Emphasis on PI3K-Akt Pathway. by Gabbouj S, Ryhänen S, Marttinen M, Wittrahm R, Takalo M, Kemppainen S, Martiskainen H, Tanila H, Haapasalo A, Hiltunen M, Natunen T. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6591470.txt.

Introduction

Gabbouj and co-authors review the insulin signaling failure shared by diabetes and Alzheimer's disease, writing in Frontiers in Neuroscience. Type 2 diabetes multiplies Alzheimer's risk two to four times. The link runs through one pathway: insulin speaks to cells via PI3K and Akt, and that conversation fades in both diseases.

In Alzheimer's brains, PI3K components are reduced and Akt activation is blunted, alongside the familiar plaques and tangles. Feeding Alzheimer's-model mice a high-fat, high-sugar Western diet distorts the same pathway. The review maps PI3K-Akt's jobs in neurons, where it supports growth and synapses, and in microglia and astrocytes. A hopeful note closes it: insulin delivered through the nose, straight toward the brain, has improved memory in mouse and human trials.

Catalog record

CREATORGabbouj S, Ryhänen S, Marttinen M, Wittrahm R, Takalo M, Kemppainen S, Martiskainen H, Tanila H, Haapasalo A, Hiltunen M, Natunen T.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6591470

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway By Sami Gabbouj, Simo Ryhänen, Mikael Marttinen, Rebekka Wittrahm, Mari Takalo, Susanna Kemppainen, Henna Martiskainen, Heikki Tanila, Annakaisa Haapasalo, Mikko Hiltunen, Teemu Natunen Published in: Frontiers in Neuroscience DOI: 10.3389/fnins.2019.00629 ABSTRACT Abstract Alzheimer’s disease (AD) and type 2 diabetes (T2D) are both diseases with increasing prevalence in aging populations. T2D, characterized by insulin resistance and defective insulin signaling, is a common co-morbidity and a risk factor for AD, increasing the risk approximately two to fourfold. Insulin exerts a wide variety of effects as a growth factor as well as by regulating glucose, fatty acid, and protein metabolism. Certain lifestyle factors, physical inactivity and typical Western diet (TWD) containing high fat and high sugar are strongly associated with insulin resistance and T2D. The PI3K-Akt signaling pathway is a major mediator of effects of insulin and plays a crucial role in T2D pathogenesis. Decreased levels of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) subunits as well as blunted Akt kinase phosphorylation have been observed in the AD brain, characterized by amyloid-β and tau pathologies. Furthermore, AD mouse models fed with TWD have shown to display altered levels of PI3K subunits. How impaired insulin-PI3K-Akt signaling in peripheral tissues or in the central nervous system (CNS) affects the development or progression of AD is currently poorly understood. Interestingly, enhancement of PI3K-Akt signaling in the CNS by intranasal insulin (IN) treatment has been shown to improve memory in vivo in mice and in human trials. Insulin is known to augment neuronal growth and synapse formation through the PI3K-Akt signaling pathway. However, PI3K-Akt pathway mediates signaling related to different functions also in other cell types, like microglia and astrocytes. In this review, we will discuss the most prominent molecular mechanisms related to the PI3K-Akt pathway in AD and how T2D and altered insulin signaling may affect the pathogenesis of AD. Keywords: Alzheimer’s disease, type 2 diabetes, insulin, phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K), Akt (Protein kinase B, PKB), glucose metabolism, neuroinflammation, autophagy INTRODUCTION Both Alzheimer’s disease (AD) and type 2 diabetes (T2D) are diseases reaching epidemic proportions. The main neuropathological findings in AD, the most common form of dementia, are β-amyloid plaques, composed of extracellular aggregates of the β-amyloid (Aβ) peptide, and intracellular neurofibrillary tangles (NFT) formed of hyperphosphorylated tau protein (Hardy and Selkoe, 2002). However, there are several other pathological features related to AD, including loss of synapses and neurons, inflammatory activation of microglia and astrocytes as well as impairment in glucose metabolism and insulin-phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3)-Akt signaling in the brain (Mosconi et al., 2008; Serrano-Pozo et al., 2011; Talbot et al., 2012). Type 2 diabetes is a complex, age- and lifestyle-related chronic disease. It is characterized by increased glucose and insulin levels in the blood, insulin resistance, metabolic abnormalities, and chronic inflammation (Sjöholm and Nyström, 2006; Ashcroft and Rorsman, 2012). T2D is one of the most important co-morbidities of AD, increasing the risk of AD two to fourfold (Craft, 2007; Sims-Robinson et al., 2010). Lifestyle factors, such as physical inactivity and excess calories gained from the typical Western diet (TWD), play a central role in T2D (Khazrai et al., 2014). Several in vivo studies in AD mouse models have shown that TWD induces T2D phenotype and exacerbates memory impairments, which are linked to altered PI3K-Akt signaling in the brain (Kang et al., 2017; Kothari et al., 2017; Salas et al., 2018). Insulin is a crucial factor controlling blood glucose levels and it facilitates cellular glucose uptake in peripheral tissues by activating the PI3K-Akt pathway (Kim and Feldman, 2012). In the brain, insulin does not have a major role in glucose metabolism. However, insulin and the PI3K-Akt signaling pathway play a significant role in neuronal health as well as synapse formation and maintenance (Van Der Heide et al., 2005; Chiu et al., 2008; Lee et al., 2011). Apart from neurons, PI3K-Akt signaling pathway also plays a central role in other cell types in the brain and TWD has been shown to affect, e.g., the function of microglia (Spagnuolo et al., 2015; Spencer et al., 2019). Imaging studies have shown that T2D is often associated with changes in the brain that are typically detected in patients with AD and related dementias, including decreased hippocampal volume, reduced glucose metabolism, and changes in cerebral blood flow (Baker et al., 2011; Moran et al., 2013; Willette et al., 2015). Furthermore, alterations in the insulin signaling pathway as well as decreased levels of insulin and insulin receptors (IR) have been observed in the AD brain (Steen et al., 2005; Talbot et al., 2012). Similarly, to T2D, other abnormalities such as metabolic stress and inflammation are also characteristic in AD (Moloney et al., 2010; Talbot et al., 2012). However, the relationship between T2D and the main neuropathological finding in AD, cerebral Aβ accumulation, remains unclear. While most of the studies have reported no association, two studies have found a significant correlation between peripheral insulin resistance and brain Aβ levels as measured by Pittsburgh compound B-positron emission tomography (PiB-PET) (Willette et al., 2015; Ekblad et al., 2018). The impaired insulin-PI3K-Akt signaling observed in the AD brain has led to clinical trials studying whether the enhancement of this pathway using intranasal insulin (IN) treatment is beneficial. Intranasally administered insulin reaches the brain via the olfactory and trigeminal nerves (Lochhead et al., 2019). Further, doses up to 40 IU in elderly subjects seem not to induce systemic hypoglycemia (Craft et al., 2012). The majority of results from studies in cognitively healthy humans as well as in AD patients are encouraging, suggesting that IN enhances memory and cognition (reviewed by Chapman et al., 2017). However, the effects appear to depend on the dose and the dose regime (acute vs. repeated), cognitive test used, and the APOE genotype. Interestingly, in a preclinical APP/PS1 AD mouse model, IN treatment led to the specific activation of the Akt2 isoform (Gabbouj et al., 2019). This suggests that Akt kinases may have isoform-specific roles in insulin signaling in the brain. Furthermore, the same study revealed differential effects of IN on the expression profile of homeostatic microglia and the markers of autophagy in the hippocampus of WT and APP/PS1 mice. Despite the strong epidemiological association between AD and T2D, the underlying molecular mechanisms are still not fully understood. It is probable that T2D affects the development and progression of AD and related disorders via several mechanisms, some of which may be directly or indirectly linked to the insulin-PI3K-Akt signaling pathway. The aim in this review article is to summarize and discuss the effects of altered insulin-PI3K-Akt signaling and T2D on the pathogenesis of AD. GLUCOSE METABOLISM AND INSULIN RESISTANCE IN THE BRAIN Common findings in T2D are hyperglycemia and insulin resistance, meaning that peripheral tissues do not respond normally to insulin in order to take up glucose from the blood. Insulin resistance can be clinically assessed using, e.g., the homeostatic model assessment for insulin resistance (HOMA-IR) from fasting insulin and glucose levels (Matthews et al., 1985). However, the definition of insulin resistance in the brain is not as clear. While glucose uptake in peripheral tissues is heavily dependent on insulin, glucose uptake in the brain is mainly independent of insulin (Kim and Feldman, 2012).

Read the complete text